Successes and limitations of targeted cancer therapy in breast cancer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Progress in tumor research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000355896PMID 24727984
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088.

  2016cited by this paper
• Successes and limitations of targeted cancer therapy

  2014cited by this paper
• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

  2012cited by this paper
• Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

  2012cited by this paper
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

  2012cited by this paper
• Trastuzumab emtansine for HER2-positive advanced breast cancer.

  2012cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

  2011cited by this paper
• Should liver metastases of breast cancer be biopsied to improve treatment choice?

  2011cited by this paper
• Body Size, Physical Activity, and Risk of Triple-Negative and Estrogen Receptor–Positive Breast Cancer

  2011cited by this paper
• Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

  2011cited by this paper
• Biology-driven phase II trials: what is the optimal model for molecular selection?

  2011cited by this paper
• Reproductive history and risk of three breast cancer subtypes defined by three biomarkers

  2011cited by this paper
• A review of PARP inhibitors: from bench to bedside.

  2011cited by this paper
• A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

  2011cited by this paper
• Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

  2011cited by this paper
• The evolving war on cancer.

  2011cited by this paper
• Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study

  2011cited by this paper
• Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

  2010cited by this paper
• Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines

  2010cited by this paper
• Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

  2010cited by this paper
• Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft

  2010cited by this paper
• A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.

  2010cited by this paper
• Deconstructing the molecular portraits of breast cancer

  2010cited by this paper
• Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

  2010cited by this paper
• Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

  2010cited by this paper
• Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  2010cited by this paper
• Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer

  2010cited by this paper
• Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

  2010cited by this paper
• Supervised risk predictor of breast cancer based on intrinsic subtypes.

  2009cited by this paper
• ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors

  2009cited by this paper
• Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

  2009cited by this paper
• Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer

  2009cited by this paper
• Design and analysis issues in genome-wide somatic mutation studies of cancer.

  2009cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

  2009cited by this paper
• Gene-expression signatures in breast cancer.

  2009cited by this paper
• Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

  2009cited by this paper
• Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

  2009cited by this paper
• Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

  2009cited by this paper
• Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.

  2009cited by this paper
• Results of randomized phase II trial combining Iressa® (gefitinib) and arimidex in women with advanced breast cancer (ABC). EORTC protocol 10021.

  2009cited by this paper
• Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  2008cited by this paper
• Epidemiology of basal-like breast cancer

  2008cited by this paper
• Crosstalk Between IGF1R and Estrogen Receptor Signaling in Breast Cancer

  2008cited by this paper
• Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.

  2008cited by this paper
• IGF-1 Receptor Inhibitors in Clinical Trials—Early Lessons

  2008cited by this paper
• An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

  2008cited by this paper
• Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

  2008cited by this paper
• A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.

  2007cited by this paper
• Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

  2007cited by this paper
• The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers

  2007cited by this paper
• Inhibition of Estradiol Receptor/Src Association and Cell Growth by an Estradiol Receptor α Tyrosine-Phosphorylated Peptide

  2007cited by this paper
• Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b.

  2006cited by this paper
• Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells

  2006cited by this paper
• Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

  2006cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.

  2005cited by this paper
• Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.

  2005cited by this paper
• Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.

  2005cited by this paper
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

  2004cited by this paper
• Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

  2004cited by this paper
• Cancer genes and the pathways they control

  2004cited by this paper
• Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation*

  2003cited by this paper
• The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum

  2002cited by this paper
• Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.

  1996cited by this paper
• Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.

  1996cited by this paper
• Tyrosine kinase/p21ras/MAP‐kinase pathway activation by estradiol‐receptor complex in MCF‐7 cells.

  1996cited by this paper
• Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression.

  1995cited by this paper
• The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3.

  1991cited by this paper

• Ferroptosis-centered strategies: redefining therapeutic resistance & adaptation in modern oncology

  2026cites this paper
• SFG enhances apoptosis of hepatocellular carcinoma by inhibiting tunneling nanotubes-mediated mitochondrial transport in the tumor microenvironment

  2026cites this paper
• Anticancer properties of phenolic acids and cell death signaling pathways: A 20-year bibliometric analysis (2003–2023)

  2025cites this paper
• Breaking Barriers in Breast Cancer: Multi-Targeted Therapeutic Insights.

  2025cites this paper
• Dubiusine isolated from Adenoon indicum dalz plant induces apoptosis in human colon cancer cells.

  2025cites this paper
• Bosutinib: Transforming the Therapeutic Landscape for HER2-Positive and Triple-Negative Breast Cancer

  2025cites this paper
• The cytotoxicity effect and identification of bioactive compounds of Prismatomeris glabra crude leaf extracts against breast cancer cells

  2024cites this paper
• Self-healable, stimuli-responsive bio-ionic liquid and sodium alginate conjugated hydrogel with tunable Injectability and mechanical properties for the treatment of breast cancer.

  2024cites this paper
• Fluorescence in neurosurgery: its therapeutic and diagnostic significance – a comprehensive review

  2024cites this paper
• Phyto-Mediated Green Synthesis of Silver Nanoparticles Using an Aqueous Leaf Extract of Momordica cymbalaria: Antioxidant, Cytotoxic, Antibacterial, and Photocatalytic Properties

  2024cites this paper
• Eco-friendly green synthesis of silver nanoparticles from Aegle marmelos leaf extract and their antimicrobial, antioxidant, anticancer and photocatalytic degradation activity

  2023cites this paper
• LINC-PINT suppresses breast cancer cell proliferation and migration via MEIS2/PPP3CC/NF-κB pathway by sponging miR-576-5p.

  2023cites this paper
• Nanotechnology revolutionises breast cancer treatment: harnessing lipid-based nanocarriers to combat cancer cells

  2023cites this paper
• A review of FDA approved drugs and their formulations for the treatment of breast cancer

  2023cites this paper
• Thermosensitive and antioxidant wound dressings capable of adaptively regulating TGFβ pathways promote diabetic wound healing

  2023cites this paper
• Generation and Characterization of Engineered Ubiquitin Variants to Modulate the Ubiquitin Signaling Cascade.

  2023cites this paper
• Reptiles as Promising Sources of Medicinal Natural Products for Cancer Therapeutic Drugs

  2022cites this paper
• Black seeds of Nigella sativa: A remedy for advanced cancer therapeutics with special reference to nanotechnology

  2022cites this paper
• Assessment of Pharmacological Interactions between SIRT2 Inhibitor AGK2 and Paclitaxel in Different Molecular Subtypes of Breast Cancer Cells

  2022cites this paper
• Iron Overload and Breast Cancer: Iron Chelation as a Potential Therapeutic Approach

  2022cites this paper
• The EDN1/EDNRA/β-arrestin axis promotes colorectal cancer progression by regulating STAT3 phosphorylation

  2022cites this paper
• In vitro evaluation of immunomodulatory, anti-diabetic, and anti-cancer molecular mechanisms of Tribulus terrestris extracts

  2022cites this paper
• Effect of platelet exosomes loaded with doxorubicin as a targeted therapy on triple-negative breast cancer cells

  2022cites this paper
• Functional Attributes of Myco-Synthesized Silver Nanoparticles from Endophytic Fungi: A New Implication in Biomedical Applications

  2021cites this paper
• Review of the Mechanism of Nanocarriers and Technological Developments in the Field of Nanoparticles for Applications in Cancer Theragnostics.

  2021cites this paper
• The Comprehensive “Omics” Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy

  2021cites this paper
• Small Molecule-Targeted Therapies for GI Cancers: Success and Failures

  2020cites this paper
• Human Plasma-Derived 3D Cultures Model Breast Cancer Treatment Responses and Predict Clinically Effective Drug Treatment Concentrations

  2020cites this paper
• Rationally designed curcumin laden glycopolymeric nanoparticles: Implications on cellular uptake and anticancer efficacy

  2020cites this paper
• Identification of potential anti-leishmanial agents using computational investigation and biological evaluation against trypanothione reductase

  2020cites this paper
• Synthesis and analysis of silver–copper alloy nanoparticles of different ratios manifest anticancer activity in breast cancer cells

  2020cites this paper
• Controlling methacryloyl substitution of chondroitin sulfate: injectable hydrogels with tunable long-term drug release profiles.

  2019cites this paper
• Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer

  2019cites this paper
• Negative Regulation Of Nk Cell Activation By Cbl-B And Tam Receptors

  2019cites this paper
• Do We Need Optoacoustic Assessment of Hypoxia to Differentiate Molecular Subtypes of Breast Cancer?

  2019cites this paper
• Costs and effects of intra-operative fluorescence molecular imaging – A model-based, early assessment

  2018cites this paper
• Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials

  2018cites this paper
• Chrysophanol selectively represses breast cancer cell growth by inducing reactive oxygen species production and endoplasmic reticulum stress via AKT and mitogen‐activated protein kinase signal pathways

  2018cites this paper
• T-Type voltage gated calcium channels: a target in breast cancer?

  2018cites this paper
• Preclinical study of a Kv11.1 potassium channel activator as antineoplastic approach for breast cancer

  2017cites this paper
• Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers

  2017cites this paper
• Tumor–stroma crosstalk: targeting stroma in breast cancer

  2014cites this paper
• Small molecule inhibitors as emerging cancer therapeutics

  2014cites this paper
• Digital Commons

  year unknowncites this paper